Is The UK Life Sciences Sector Set To Recover In 2026? – An Analysis Of Funding, Patent Filings And Growth
The UK life-sciences sector appears to be entering a selective recovery period post-pandemic. Private financing has strengthened, and available data suggests capital may be reaching a broader range of companies. However, the recovery remains uneven; investors are concentrating larger sums into companies with credible platforms, mature assets or clear routes to commercial value, and a robust intellectual property portfolio.
How the post-pandemic funding cycle shaped today’s market
Understanding the current financing environment requires looking back at the period following the COVID-19 pandemic. During this period, life sciences benefited from strong investor interest. Low interest rates, combined with a global focus on healthcare innovation, drove substantial investment into therapeutics, vaccines, diagnostics and platform technologies.
From 2022 onwards, market conditions shifted considerably. Rising interest rates made lower-risk assets more attractive, while investors became more cautious about long development timelines and the considerable capital requirements associated with biotech innovation. This created a more difficult market for early-stage life-science companies, with fewer IPO opportunities and increased pressure on companies to conserve cash.
By 2025, there were signs of consolidation, but not of a broad recovery. Funding was concentrated among a relatively small number of companies, with many early-stage businesses continuing to face financing challenges1. This was further evidenced by the absence of UK biotech IPOs for a third consecutive year.
Funding direction in 2026
However, early signs for 2026 appear more positive. Recent data shows that UK biotech venture investment has strengthened, with private financing contributing to a more optimistic outlook compared to recent years. According to the Bio Industry Association (BIA), which is the UK’s leading life sciences and biotech trade association, representing over 600 member organisations across the sector, UK biotech equity financing reached £552m in Q1 2026, and venture capital rose to £516m (Figure 1), a 17% quarter-on-quarter increase2. The BIA’s data on deal count supports this outlook. It shows 53 deals so far in 2026, compared with 58 across all of 20252, indicating that capital is being distributed across a wider number of transactions and a varying amount of capital per deal (Figure 2).
Momentum continued into Q2 2026, with UK biotech companies raising £2.11 billion in total equity financing, including £2.05 billion in venture capital funding2; the strongest quarterly venture total in 5 years (Figure 1). These figures were heavily influenced by Isomorphic Labs, the London-based AI drug-discovery company, which raised £1.6 billion Series B financing.
Figure 1: as from https://biotechfinance.org/
Figure 2: as from https://biotechfinance.org/
Nevertheless, excluding the Isomorphic Labs financing, UK biotech companies raised £498 million in venture capital during Q2 2026, almost double the £279 million raised in Q2 2025 2(Figure 3). The distribution of this is beginning to show positive signs of an increase in start-up funding, where data suggests a positive trend of more frequent, lower capital investment. This is a hopeful indicator of a broader and more balanced funding landscape.
Figure 3: as from https://biotechfinance.org/
Where is the investment coming from?
The trend towards increased investment activity is also reflected in public-sector and corporate investment announcements. From a press release in July 2026, the government highlighted that the UK Life Sciences sector has attracted £3bn in investment over 12 months. The announcement linked the investment to goals including job creation, faster clinical development and earlier patient access to new treatments3.
The UK government also emphasised the life-science sector's economic importance, noting annual turnover of approximately £147b and employment of around 360,000 people alongside support through measures such as the £520m Life Sciences Innovative Manufacturing Fund (announced 2024)4. The announcement cited £300m of backing from AstraZeneca for its Cambridge and Macclesfield facilities; Moderna’s innovation centre in Harwell, supported by a £1b UK R&D investment over 10 years; and UCB’s £500m investment in an R&D hub in Windlesham, Surrey3.
These investments demonstrate continued confidence in the UK's life-sciences infrastructure and suggest that capital is increasingly being directed towards organisations capable of supporting large-scale research, manufacturing and commercialisation activities. They also raise the possibility that future growth may extend beyond the traditional Oxford-Cambridge-London "golden triangle", creating new opportunities across the UK. However, the Cambridge-focused investment remains significant, a point which is further amplified by the recent announcement by a pharmaceutical giant, GSK to move its headquarters from Stevenage to Cambridge5. This follows the move by another pharmaceutical giant, Astra Zeneca, which announced plans to expand its Cambridge operations earlier this year6.
Do patent filings support the recovery narrative?
Patent activity offers a useful perspective on whether funding improvements are translating into innovation and the published European Patent Office (EPO) data can provide a useful indicator of commercially significant research within the UK. However, EPO filing data does not capture all UK life-sciences innovation as it does not represent UK-only filings, only those filed at the EPO and designated to the UK.
Looking at the UK life science EPO filings from 2023 (combining medical technology, biotech and pharmaceuticals) a 4.9% reduction in filings was observed from the 1127 applications in 2023 to 1072 applications in 20247. This follows the narrative explored regarding the post-COVID funding scarcity. There appears to be a recovery in 2025, where filings increased 3.5% to 1109, but not yet reaching 2023 levels7. The current pattern broadly mirrors the wider financial landscape: a period of caution and consolidation after 2022 followed by signs of a slow renewing in confidence. Importantly, 2025 does not yet represent returns to previous filing highs, but it does suggest that innovation activity has remained surprisingly robust as a whole and has not shown significant fluctuations such as that seen in the funding landscape.
Looking further into the data, the recovery appears uneven across the sector. Between 2024 and 2025, medical technology filings increased by almost 10% and biotechnology filings rose by more than 7%, while pharmaceuticals declined by 10%8. This suggests that recent growth is being driven primarily by biotechnology and technology-enabled healthcare innovation rather than traditional drug development alone. The trend aligns with current investment patterns, where capital has increasingly flowed towards platform technologies, diagnostics and businesses developing innovative technologies, supported by clearer pathways to commercialisation. Taken together with the financial data, the patent data supports the view that the UK life-sciences sector is recovering, but that recovery is strongest in biotechnology and medical technology rather than across the sector.
Key Takeaways
In conclusion, the funding data, investment announcements and patent trends demonstrate a selective recovery within the UK life sciences sector. Growth appears to be visible, but funding is more confident in companies that are better established with credible platforms and clearer routes to commercialisation.
The data discussed suggests the next phase of growth is therefore likely to be led by biotechnology, diagnostics and, unsurprisingly, AI-enabled technologies that can show both scientific value and commercial scalability. This is supported by the Isomorphic Labs’ financing, while the distribution in seed and smaller rounds of funding suggests confidence may be improving across the board and the change in focus of technology filings at the EPO, notably the significant decrease shown in pharmaceutical filings.
The government and corporate investments also indicate that infrastructure will remain important, as discussed with the investment into R&D hubs and manufacturing capacity. However, while there is some funding arising outside of the expected regions by large companies self-investing, there is a clear and maintained focus on life science development within Cambridge.
Patent data reinforces the cautiously optimistic view. Although filings are not a direct measurement, they suggest innovation has been able to remain resilient through the post-pandemic troubles. Stronger medical and biotechnology filings further imply the shift in focus to a more technology and AI funding landscape.
Overall, the sector appears to be continuing its selective recovery. Private financing has grown stronger, but the lack of a broad IPO revival suggests there is still significant caution. The companies best placed to benefit are likely those that combine science with solid commercial strategy, robust intellectual property with wide territorial cover, and the ability to scale into development, manufacturing and market access. The continuing Cambridge focus, reinforced by large corporate commitments and relocation of major activity in the area, suggests that future growth remains firmly influenced by established life-sciences clusters. In this environment, companies seeking funding will need to show not only scientific promise, but also commercially aligned intellectual property strategies, with ownership clearly documented and freedom-to-operate risks considered early. In a selective market, strong patent protection and a robust patent portfolio can help reduce investor risk and support the move from innovation to commercialisation.
Written by Will Stobbart, PhD student and Intern, and Joeeta Murphy, Director and Head of Life Sciences.
References
[2] https://biotechfinance.org/
[4] https://www.gov.uk/government/publications/life-sciences-innovative-manufacturing-fund-lsimf
[6] https://www.bbc.co.uk/news/articles/cx2kdnxnek1o
[7] https://www.epo.org/en/about-us/statistics/patent-index-2024
[8] https://www.epo.org/en/about-us/statistics/data-download